Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Charles River Laboratories International, Inc.

Market Cap 9.03B 7.8B 7.19B 6.73B 12.61B 858B 12.81B 84.88B 33.09B 418B 33.9B 33.18B 1,447B P/E Ratio 2026 *
30.6x
P/E Ratio 2027 * 20.4x
Enterprise Value 10.84B 9.37B 8.63B 8.08B 15.14B 1,031B 15.37B 102B 39.73B 502B 40.7B 39.83B 1,737B EV / Sales 2026 *
2.81x
EV / Sales 2027 * 2.68x
Free-Float
97%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 56 2026-05-04
Director of Finance/CFO 58 2026-04-05
Chief Tech/Sci/R&D Officer 45 2026-01-11
Director TitleAgeSince
Chairman 75 1999-12-31
Director/Board Member 56 2026-05-04
Chairman 69 2026-05-04
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 9.06B
-0.35%+0.97%-15.96%-12.73% 42.96B
+3.11%+3.11%+274.29%+507.94% 31.73B
+0.22%-1.08%+14.03%-14.37% 30.22B
+1.62%-2.08%-4.36%+24.05% 28.94B
+4.09%+0.93%+10.83%+18.78% 23.87B
-1.63%+2.88%+53.73%+114.36% 13.57B
-0.40%-1.29%+6.06%+7.59% 12.96B
+1.14%+3.62% - - 13.39B
-0.74%-1.62%+105.71%+76.01% 12.2B
Average +0.71%+0.64%+55.54%+90.21% 23.31B
Weighted average by Cap. +0.98%+0.69%+54.32%+95.99%

Financials

2026 *2027 *
Net sales 3.85B 3.33B 3.07B 2.87B 5.38B 366B 5.47B 36.22B 14.12B 178B 14.47B 14.16B 617B 3.92B 3.39B 3.12B 2.92B 5.48B 373B 5.56B 36.87B 14.38B 182B 14.73B 14.41B 629B
Net income 285M 246M 227M 212M 398M 27.1B 404M 2.68B 1.04B 13.19B 1.07B 1.05B 45.67B 417M 360M 332M 311M 583M 39.66B 592M 3.92B 1.53B 19.3B 1.57B 1.53B 66.84B
Net Debt 1.81B 1.57B 1.44B 1.35B 2.53B 172B 2.57B 17.03B 6.64B 83.85B 6.8B 6.66B 290B 1.47B 1.27B 1.17B 1.09B 2.05B 140B 2.08B 13.8B 5.38B 67.92B 5.51B 5.39B 235B
Logo Charles River Laboratories International, Inc.
Charles River Laboratories International, Inc. specializes in the development of products and services in the field of research and non-clinical drug development for pharmaceutical companies, government agencies and academic institutions. Net sales break down by activity as follows: - discovery and safety assessment services (59.8%): discovery services for the identification, screening and selection of main compounds for the development of new drug candidates, and in vivo and in vitro testing, including pharmacokinetic, bioanalytical, metabolic, toxicological and pathological studies, for the safety assessment of pharmaceutical products, medical devices, animal health products, chemical and agrochemical products and biocides; - development and sale of research models and related services (21.1%): mice, rats, immunodeficient models, rabbits, guinea pigs, hamsters, etc. The group also offers primary cells and specialized products (bioconservation products, freezing media for cell cultures, antigens, peptides, humanized mouse models, etc.) for the development and manufacture of new cell therapies ; - development of solutions used in drug manufacturing processes (19.1%): products and services for microbiological testing, in vitro testing, endotoxin testing, microbial identification, development, manufacturing of avian vaccines, etc. The group also offers contract manufacturing services for cell and gene therapies. Net sales break down by source of income between sales of services (80.9%) and sales of products (19.1%). Net sales are distributed geographically as follows: the United States (53.3%), Europe (27.5%), Canada (12.5%), Asia/Pacific (5.1%), and other (1.6%).
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
187.51USD
Average target price
212.27USD
Spread / Average Target
+13.20%

Quarterly revenue - Rate of surprise

- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!